title: Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
abstract: Two decades of epidemiological research shows that silent cerebrovascular disease is common and is associated with future risk for stroke and dementia. It is the most common incidental finding on brain scans. To summarize evidence on the diagnosis and management of silent cerebrovascular disease to prevent stroke, the Stroke Council of the American Heart Association convened a writing committee to evaluate existing evidence, to discuss clinical considerations, and to offer suggestions for future research on stroke prevention in patients with 3 cardinal manifestations of silent cerebrovascular disease: silent brain infarcts, magnetic resonance imaging white matter hyperintensities of presumed vascular origin, and cerebral microbleeds. The writing committee found strong evidence that silent cerebrovascular disease is a common problem of aging and that silent brain infarcts and white matter hyperintensities are associated with future symptomatic stroke risk independently of other vascular risk factors. In patients with cerebral microbleeds, there was evidence of a modestly increased risk of symptomatic intracranial hemorrhage in patients treated with thrombolysis for acute ischemic stroke but little prospective evidence on the risk of symptomatic hemorrhage in patients on anticoagulation. There were no randomized controlled trials targeted specifically to participants with silent cerebrovascular disease to prevent stroke. Primary stroke prevention is indicated in patients with silent brain infarcts, white matter hyperintensities, or microbleeds. Adoption of standard terms and definitions for silent cerebrovascular disease, as provided by prior American Heart Association/American Stroke Association statements and by a consensus group, may facilitate diagnosis and communication of findings from radiologists to clinicians.
authors.forename: Eric E
authors.initials: EE
authors.lastname: Smith
authors.forename: Gustavo
authors.initials: G
authors.lastname: Saposnik
authors.forename: Geert Jan
authors.initials: GJ
authors.lastname: Biessels
authors.forename: Fergus N
authors.initials: FN
authors.lastname: Doubal
authors.forename: Myriam
authors.initials: M
authors.lastname: Fornage
authors.forename: Philip B
authors.initials: PB
authors.lastname: Gorelick
authors.forename: Steven M
authors.initials: SM
authors.lastname: Greenberg
authors.forename: Randall T
authors.initials: RT
authors.lastname: Higashida
authors.forename: Scott E
authors.initials: SE
authors.lastname: Kasner
authors.forename: Sudha
authors.initials: S
authors.lastname: Seshadri
mesh_terms: D000572:American Heart Association; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods; D006282:Health Personnel / Q000592:standards; D006801:Humans; D059906:Neuroimaging / Q000379:methods; D012307:Risk Factors; D020521:Stroke / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000517:prevention & control*; D014481:United States / Q000453:epidemiology
keywords: AHA Scientific Statements; anticoagulants; brain infarction; cerebrovascular disorders; prevention and control; white matter